Kaken Pharmaceutical (4521) Q3 2026 earnings summary

Executive summary

• Net sales for the nine-month period ended December 31, 2025, were ¥57,617 million, down 24.2% year-over-year.

• Operating profit dropped 97.8% to ¥554 million, and profit attributable to owners fell 92.7% to ¥1,398 million compared to the same period last year.

• Comprehensive income decreased 89.3% year-over-year to ¥2,002 million.

Financial highlights

• Gross profit for the nine-month period was ¥26,785 million, down from ¥49,193 million year-over-year.

• Selling, general and administrative expenses increased to ¥30,277 million from ¥23,772 million, with R&D expenses rising to ¥15,645 million.

• Basic earnings per share for the period was ¥36.87, compared to ¥506.31 in the prior year.

Outlook and guidance

• Full-year forecast for fiscal year ending March 31, 2026: net sales of ¥86,300 million (up 8.2% year-over-year), operating profit of ¥2,100 million (up 90.0%), and profit attributable to owners of ¥2,300 million (up 83.5%).

• Basic earnings per share forecasted at ¥60.74 for the full year.